Abstract
Adaptive responding to stressors is of fundamental importance to the survival of the species. Aberrant hyperactivation of corticotropin releasing factor type 1 (CRF1) receptors in dysfunctional stress response system (SRS) pathways may contribute to stress-related psychopathology and therefore CRF1 receptor antagonists (CRAs) may be useful in their treatment. The status of nonpeptidic, orally active, brain-penetrating CRAs being developed for the treatment of depression, anxiety, irritable bowel syndrome and drug abuse is reviewed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
